On 7 May 2014 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-44 (benefit assessment of ipilimumab, new therapeutic indication) and for Commission A14-11 (Addendum to Commission A13-44 [ipilimumab, new therapeutic indication]).
http://ift.tt/2ruYywh
Πέμπτη 15 Ιουνίου 2017
Second Addendum to Commission A13-44 (Ipilimumab, New Therapeutic Indication) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου